Characterizing the Genomic Landscape of Brain Glioma With Circulating Tumor DNA From Tumor In Situ Fluid
Authors:
Open Access
- 31 March 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Tumor in situ fluid (TISF) refers to the fluid at the local surgical cavity. We evaluated the feasibility of TISF-derived circulating tumor DNA (ctDNA) characterizing the genomic landscape for glioma. This retrospective study included TISF and tumor samples from 10 patients with glioma, we extracted cell-free DNA (cfDNA) from the TISF and then performed deep sequencing on that. And we compared genomic alterations between TISF and tumor tissue. Results showed that the concentration of cfDNA fragments from the patients for TISF ranged from 7.2 to 1,397 ng/ml. At least one tumor-specific mutation was identified in all 10 patients (100%). Further analysis of TISF ctDNA revealed a broad spectrum of genetic mutations, which have been reported to have clinical relevance. The analysis of concordance between TISF and tumor tissue reflected the spatiotemporal heterogeneity of glioma. Collectively, TISF ctDNA was a powerfully potential source for characterizing the genomic landscape of glioma, which provided new possibilities for precision medicine in patients with glioma.Keywords
This publication has 23 references indexed in Scilit:
- Diffuse Glioma Heterogeneity and Its Therapeutic ImplicationsCancer Discovery, 2021
- The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer PatientsCancers, 2020
- Management of glioblastoma: State of the art and future directionsCA: A Cancer Journal for Clinicians, 2020
- Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastomaActa Neuropathologica Communications, 2020
- Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal CancerGastroenterology, 2020
- White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancerNature Communications, 2020
- Liquid biopsy and minimal residual disease — latest advances and implications for cureNature Reviews Clinical Oncology, 2019
- Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNAActa Neuropathologica, 2018
- Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapynpj Breast Cancer, 2017
- Spatiotemporal genomic architecture informs precision oncology in glioblastomaNature Genetics, 2017